Lusochimica

What Lusochimica does

Lusochimica S.p.A. is an Italian manufacturer of bulk Active Pharmaceutical Ingredients (APIs) founded in 1964 in Lomagna and operating since 1984 as a wholly-owned subsidiary of the Menarini Group. The company runs three GMP-certified manufacturing plants in Lomagna, Pisa (incorporated from Laboratori Guidotti Fine Chemicals in 2009), and Casaletto Lodigiano/Lodichem (acquired in 2016), plus a sales and marketing office in Rozzano (Milan). Its core capability is total synthetic organic chemistry focused on niche, high-value APIs, with proprietary strengths in flow chemistry and biocatalysis demonstrated through the EU4Health-funded SmartNEBI project. The product portfolio spans marketed APIs (calcium channel blockers, bronchodilators, antifungals, antibiotics), a development pipeline targeting cystic fibrosis, multiple sclerosis, IBS, and oncology indications, and custom manufacturing/CDMO services from process design through commercial production. The company is certified under EU GMP, ISO 50001, ISO 14001, and ISO 45001, with historical inspections by the US FDA, KFDA, and Italian MoH.

The business operates a B2B Contract Development and Manufacturing Organization model serving both large multinational pharmaceutical corporations and small local pharmaceutical companies, using a horizontal segmentation approach. Revenue is generated through API manufacturing and supply (transaction-based), custom manufacturing/CDMO services (project-based professional services), and a development pipeline (future transaction revenue). Pricing is quote-based and negotiated individually per contract, with no publicly disclosed rates. Go-to-market is primarily direct enterprise sales via a Commercial Director and Area Managers, complemented by participation in major industry events (CPHI Worldwide in Milan, CPHI China, CPHI Japan, DCAT) and a corporate LinkedIn presence. All customer relationships are managed directly without intermediaries or third-party distributors. Strategic positioning emphasizes regulatory compliance, Italian quality heritage, and innovation in sustainable synthesis methods as competitive differentiators.

Name

Lusochimica

Legal name

Lusochimica S.p.A.

Website

https://lusochimica.it

Company type

Private

Founded year

1964

Operating status

Operating

Headcount range

51–100 employees

Short description

Lusochimica S.p.A. is an Italian API manufacturer and CDMO, founded in 1964 and wholly owned by Menarini Group, operating three GMP-certified plants in Italy that produce niche, high-value active pharmaceutical ingredients and custom manufacturing services for global and local pharmaceutical clients.

Ownership category

akta.pro rank

Product category

Active Pharmaceutical Ingredient (API) Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule API Process Development & Route Scouting (HLAGAHAA), Small-Molecule API Commercial Manufacturing (HLAGAHAB), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Active pharmaceutical ingredients
• Pharmaceutical contract manufacturing
• API development services
• Bulk drug substances
• Custom API synthesis

Headquarters

HQ city

Lomagna

HQ country

Italy

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel

Revenue model

1. API Manufacturing and Supply: Manufacturing and supply of Active Pharmaceutical Ingredients (APIs) including a comprehensive portfolio of high-quality APIs manufactured under strict GMP compliance, ready for immediate supply to pharmaceutical clients
2. Custom Manufacturing Services: Tailored API development and manufacturing services supporting specific customer requirements from process design to commercial production. The company serves as a CDMO (Contract Development and Manufacturing Organization)
3. Products Under Development: Innovative active pharmaceutical ingredients currently in development to meet emerging therapeutic needs and future market demands, representing pipeline revenue potential

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Lusochimica S.p.A. manufactures and supplies Active Pharmaceutical Ingredients (APIs) from three Italian production plants, operating both as a producer of marketed APIs and as a Contract Development and Manufacturing Organization (CDMO). The company offers a marketed API portfolio, a pipeline of APIs under development, and tailored custom manufacturing services from process design to commercial production for pharmaceutical clients.

Product overview

Lusochimica S.p.A. is an Italian pharmaceutical manufacturer of bulk Active Pharmaceutical Ingredients (APIs) offering three integrated product lines: (1) Available APIs - a comprehensive portfolio of marketed products manufactured under EU GMP compliance including cardiovascular agents, bronchodilators, antifungals, and antibiotics; (2) Products Under Development - innovative APIs targeting emerging therapeutic areas such as cystic fibrosis, multiple sclerosis, and irritable bowel syndrome; and (3) Custom Manufacturing (CDMO) services - tailored API development and manufacturing from process design through commercial production. The company serves clients from large multinational corporations to small local companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Available APIs

Quantifiable outcome

• 60% grant funding for SmartNEBI sustainable synthesis project

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• University of Milan (Statale di Milano)coreStrategic or Co-development Partner · 9 May 2025Lusochimica has partnered with the University of Milan for the SmartNEBI project. Professor Lucia Tamborini and Professor Andrea Pinto bring expertise in flow chemistry and specifically flow biocatalysis. This collaboration merges academic excellence with the project's mission to develop sustainable Nebivolol synthesis using biocatalysis and flow chemistry. The partnership is part of the EU4Health funded project (Project number: 101201885).
• Menarini Group (A. Menarini Industrie Farmaceutiche Riunite S.r.l.)coreOthers · 1 January 1984Lusochimica has been part of Menarini Group since 1984. The company is subject to the direction and coordination of A. Menarini Industrie Farmaceutiche Riunite S.r.l. This parent company relationship has helped Lusochimica focus on becoming an international player in pharmaceutical API manufacturing.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Olon Group: Italian API manufacturer headquartered near Milan with comparable focus on generic and CDMO small-molecule APIs. Both companies are Italy-based, family/corporate-owned, and compete for the same European CDMO contract opportunities.
• Fabbrica Italiana Sintetici (FIS): Italian CDMO specializing in small-molecule APIs with similar heritage, GMP-certified Italian plants, and CDMO service offering. Direct competitor for European pharma custom manufacturing contracts in similar therapeutic categories.
• Hovione: Portuguese-headquartered CDMO with similar focus on complex small-molecule APIs, particularly niche and high-potency compounds. Comparable business model combining proprietary API development with custom manufacturing services for global pharma clients.
• Cambrex: US/EU-based small-molecule API CDMO serving pharmaceutical customers with similar custom development and manufacturing services. Direct competitor for CDMO contracts in similar therapeutic categories, though at larger scale.
• Curia (formerly AMRI): Global CDMO providing small-molecule API development and manufacturing services across multiple regulatory jurisdictions. Competes with Lusochimica for custom synthesis and commercial API supply contracts from pharmaceutical clients.
• Dipharma Francis: Italian API manufacturer with similar mid-sized CDMO profile, Italian manufacturing footprint, and focus on complex generic APIs. Direct competitor for European CDMO opportunities in similar therapeutic areas.
• Apotex Pharmachem: Canadian-headquartered API manufacturer serving global pharmaceutical clients with small-molecule API production. Comparable CDMO and commercial API offerings for generic and innovator pharma customers.
• Johnson Matthey Health: Global provider of API manufacturing services including complex small-molecule APIs and catalysts. Direct competitor in the high-value API manufacturing space, particularly for complex synthesis requiring advanced chemistry capabilities.

Broad incumbents

• Recordati: Major Italian pharmaceutical company with internal API manufacturing capabilities. While primarily a branded pharmaceutical company, Recordati's API operations and Italian heritage make it a comparable broad incumbent in the Italian pharma manufacturing landscape.
• Pfizer CentreOne: Pfizer's contract manufacturing arm offering API and finished dosage form services. As a large incumbent CDMO with broader capabilities, it competes for the same pharmaceutical custom manufacturing opportunities from a position of greater scale and geographic diversification.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lusochimica-s.p.a.

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lusochimica